Advancing Precision through Next-Generation Drug Delivery Systems
Pharma Tech Outlook
Home ยป News

Advancing Precision through Next-Generation Drug Delivery Systems

Pharma Tech Outlook | Monday, September 28, 2026

Drug delivery has become the limiting factor in translating therapeutic innovation into clinical impact. Breakthroughs in gene editing, RNA therapeutics and targeted oncology continue to outpace the systems designed to carry them, creating a widening gap between discovery and practical deployment. Many existing approaches remain constrained by invasive administration, cold-chain dependency and limited targeting precision, which collectively increase cost, reduce patient adherence and introduce variability in outcomes.

A more effective approach begins with rethinking how therapies move through the body and reach specific tissues. Delivery systems must demonstrate adaptability across multiple therapeutic modalities while maintaining control over where and how payloads are released. Platforms that can accommodate DNA, RNA, proteins and emerging gene-editing tools without requiring separate development pipelines offer a distinct advantage. Consolidation of these capabilities reduces development friction and allows organizations to scale programs without rebuilding infrastructure for each modality.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Equally important is the ability to direct therapies with accuracy. Traditional systemic delivery often results in off-target exposure, increasing the likelihood of adverse effects and diluting efficacy. Newer systems that incorporate programmable targeting mechanisms allow payloads to concentrate at specific tissues, enabling lower dosing and improved safety profiles. This precision becomes especially relevant in oncology and infectious disease, where localized intervention can alter both clinical outcomes and cost dynamics.

The route of administration also plays a decisive role in real-world adoption. Injectable therapies, while effective, introduce logistical and behavioral barriers that limit reach. Delivery systems capable of oral or intranasal administration change this equation by improving accessibility and adherence. These formats reduce reliance on trained personnel and clinical settings, expanding the feasibility of treatment across diverse healthcare environments. Stability outside of refrigerated supply chains further strengthens this advantage, particularly in regions where infrastructure constraints can delay or prevent distribution.

Manufacturing considerations remain closely tied to long-term viability. Scalable production methods that rely on established fermentation processes rather than complex cell cultures provide a clearer path to cost control and consistent output. Uniformity in particle design and reproducibility in encapsulation contribute to predictable performance during pre-clinical and clinical phases, supporting faster iteration and more efficient development cycles.

Astrid Pharma aligns with these expectations through its BioCapZ platform, which centers on a protein-based capsule designed to carry a wide range of therapeutic payloads. The platform enables oral and intranasal delivery while maintaining structural integrity in challenging biological environments, supporting broader patient access. Its modular architecture allows surface-level targeting adjustments that direct therapies toward specific tissues, reducing unintended exposure and improving treatment precision. Evidence of oral CRISPR delivery and imaging-enabled tumor targeting demonstrates its potential to integrate therapy and diagnostics within a single system.

BioCapZ’s ability to function without refrigeration and its compatibility with scalable fermentation processes strengthen its suitability for global deployment. Its design supports repeat dosing through reduced immune detection while maintaining consistent particle characteristics during manufacturing. Taken together, these attributes position Astrid Pharma as a compelling choice for organizations prioritizing adaptable, targeted and accessible drug delivery solutions.

More in News

Plenty of supplement formulations look perfect on paper. The ingredients meet spec, and then the capsules hit the filling line. Shells that vary in size cause feeding problems. The wrong shell material can hurt stability or stop the finished product from meeting labeling requirements. The formula is ready, yet production stalls. Picking a two-piece hard shell capsule maker comes down to what the shell is made of, how it runs on the line and whether supply holds up. Shell material is about more than a vegetarian label. Gelatin is still a staple in pharmaceutical manufacturing because of its cost and well-understood processing. HPMC (hydroxypropyl methylcellulose) and pullulan, the plant-based options, each bring something different. Pullulan, for one, is a good oxygen barrier, which matters for ingredients that oxidize easily. So the real question for buyers is how sensitive the formula is and where it will be stored. Plant-based shells are not all the same. Organic certification is a separate hurdle. A product full of certified organic ingredients can still run into labeling restrictions if the shell does not qualify. Anyone building an organic line needs proof that the whole capsule is certified, down to its source materials. It also pays to ask how the supplier controls raw materials and keeps them consistent from batch to batch. When material properties drift, capsule formation and filling can suffer, and more so as volumes rise. “Bright Pharma Caps makes two-piece hard shell capsules, including certified organic pullulan shells for supplement makers that need them.” Then there is size. High-speed encapsulation machines need consistent capsule geometry to separate and fill shells without constant stops. Batch-to-batch variation means more adjustments and more rejects. Ask suppliers how they hold tolerances and whether their equipment keeps variation low. Better yet, run trials on your own filling machines before signing a large supply deal. Some specialized formulas also need delayed-release shells that survive stomach acid for a set time. Those claims should be backed by dissolution testing. The risks do not stop at the factory gate either. Poor temperature or humidity control in a warehouse or truck can change how shells perform by the time they reach production. Check how the supplier ships capsules and what it does with affected lots. Steady supply matters most when you launch a new product or ramp up output. Regional stock can shorten replenishment times, though capacity plans should follow projected demand, not just current orders. Bright Pharma Caps makes two-piece hard shell capsules, including certified organic pullulan shells for supplement makers that need them. It produces its own organic pullulan in dedicated facilities, so a critical input stays under its control. Its machines run on electromagnetic rather than hydraulic systems, which cuts vibration and delivers tighter dimensional tolerances for high-speed filling. The range also covers HPMC delayed-release capsules, and organic liquid-fill options are in development. Several warehouses handle distribution, and technical support is on hand for capsule-related manufacturing questions. For nutraceutical producers that care most about organic certification, consistent filling and reliable resupply, it is a strong fit. ...Read more
In recent years, researchers at the intersection of computer science and biology have found it increasingly straightforward to obtain funding for commercializing their innovations. The approach is both simple and powerful: leveraging large datasets and machine learning to tackle persistent challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
The drug development landscape is swiftly transforming as innovative technologies and methods redefine the design and delivery of treatments. Leading this change are personalized medicine, artificial intelligence, and advanced therapies, which are providing new hope for patients and driving faster progress in healthcare. Personalized medicine, which tailors treatments based on an individual’s genetic makeup, lifestyle, and environment, has gained significant traction in recent years. Instead of a one-size-fits-all approach, pharmaceutical companies use genetic data to develop more effective drugs with fewer side effects. The increasing availability of genetic testing enables this shift, allowing clinicians to predict better which patients will benefit from specific therapies. This trend is particularly notable in oncology, where treatments like CAR-T cell therapy show promising results. Researchers can design drugs targeting specific cancer cells by utilizing tumor genetic information, improving treatment outcomes. Innovations Driven by Artificial Intelligence Artificial intelligence and machine learning are becoming game changers in drug development. These technologies help researchers examine extensive quantities of data more efficiently and accurately than conventional methods. AI can identify potential drug candidates, predict outcomes, and even suggest novel molecules for drug discovery. AI is also crucial in speeding up clinical trials. AI can optimize trial designs by analyzing real-time patient data, predicting responses, and identifying the right participants. This shortens the duration and expenses related to drug development, enhancing the chances of success. Regulatory agencies, like the U.S. Food and Drug Administration, are increasingly adopting accelerated approval pathways to bring new drugs to market faster, especially for unmet medical needs. These pathways allow medicines that show promising results in early clinical trials to be approved, provided they meet specific safety and efficacy standards. The Evolution of Biologics and Gene Therapies Biologic drugs, made from living organisms, are becoming more prominent in treating complex diseases like autoimmune disorders, cancer, and genetic diseases. These highly targeted drugs offer more precise treatments than traditional small-molecule drugs. Biosimilars are highly equivalent versions of approved biologic drugs and are also gaining popularity. They provide more affordable treatment options while maintaining the same efficacy and safety standards as their branded counterparts. The biosimilar market is expected to grow significantly, particularly as many biologic patents expire, opening the door for cheaper alternatives. Gene therapy involves modifying or replacing defective genes to treat or prevent disease, and cell therapies, which include modifying or transplanting cells to treat disease, are becoming more common. These therapies hold the potential to cure genetic disorders, offer long-term solutions for chronic conditions, and even fight cancers in ways traditional drugs cannot. ...Read more
Pharmacovigilance involves the systematic collection, monitoring, evaluation, and prevention of adverse effects associated with medications and treatments. As a vital, process-driven discipline in the pharmaceutical industry, its main objectives are to establish robust signal detection systems and leverage advanced data analytics to proactively evaluate the safety of new drugs across diverse patient populations, ultimately ensuring safer and more effective use of medications. Complex international rules, growing data quantities, numerous data sources, broader risk monitoring, and precise patient event recording worldwide are all factors increasing pressure on pharmacovigilance systems to change. Appropriate analytics are essential, but businesses often spend more on data processing than creative research and new technology, leading to less-than-ideal results. Implementing artificial intelligence and embracing emerging technologies throughout the pharmaceutical value chain can have numerous advantages. Here are some ways AI can Help enhance pharmacovigilance: An Expedited Path to the Market Drug development requires a lot of time because pharmaceutical companies benefit from competitive product-to-market lead times, which increase market share and profitability. Solutions utilizing artificial intelligence can facilitate quicker decision-making. Without sacrificing patient safety, a shorter end-to-end drug development cycle translates into a faster route to market. Cost-Effective Processes Pharmaceutical firms have historically used outsourcing or labor offshoring to meet the ever-increasing resource demands and expenses. That's one method of cost reduction. Another option is to invest in custom software solutions for automation and augmentation, which can result in noticeable cost savings and a significant return on investment. The business can lower the price of a product recall or an update to the label.  More accuracy and efficiency in PV services reduce the entire cost of the drug development process. The most significant financial impact on a pharmacovigilance budget is caused by case processing. The most important chance to reduce the expenses associated with the pharmaceutical development process may be to automate the reporting and management of safety cases using machine learning algorithms. Expedited Error-Free Reporting Using artificial intelligence technologies to automate repetitive jobs is a great idea. Human mistakes can be eliminated by automating the time-consuming and expensive direct annotation of source documents, provided that stringent guidelines are followed. The initial centralized medication safety monitoring stage is NLP, which automates safety reporting. Data-Driven Insights for Safety Due to growing data sets and sources, processing pharmacovigilance data solely using expert labor is not feasible. There is an enormous need for simplification, and data science solutions may help by offering predictions, intelligent, valuable insights, and automated analysis. Regulatory Compliance Over the past few years, pharmacovigilance activities have become increasingly expensive for pharmaceutical corporations due to the advent of stricter regulations worldwide. Businesses must continue to adhere to the ever-changing laws in many nations. A digitalized, adaptable architecture supporting the drug development process and global drug monitoring is the solution to being robust. ...Read more

Weekly Brief